• Je něco špatně v tomto záznamu ?

Are all HCL systems the same? long term outcomes of three HCL systems in children with type 1 diabetes: real-life registry-based study

A. Santova, L. Plachy, V. Neuman, M. Pavlikova, L. Petruzelkova, P. Konecna, P. Venhacova, J. Skvor, R. Pomahacova, D. Neumann, J. Vosahlo, J. Strnadel, K. Kocourkova, B. Obermannova, S. Pruhova, O. Cinek, Z. Sumnik

. 2023 ; 14 (-) : 1283181. [pub] 20231016

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc24001041

OBJECTIVE: To compare parameters of glycemic control among three types of hybrid closed loop (HCL) systems in children with T1D (CwD) using population-wide data from the national pediatric diabetes registry ČENDA. METHODS: CwD aged <19 years treated with Medtronic MiniMed 780G (780G), Tandem t:slim X2 (Control-IQ) or do-it-yourself AndroidAPS (AAPS) systems for >12 months and monitored by CGM >70% of the time were included. HbA1c, times in glycemic ranges, and Glycemia Risk Index (GRI) were used for cross-sectional comparison between the HCL systems. RESULTS: Data from 512 CwD were analyzed. 780G, Control-IQ and AAPS were used by 217 (42.4%), 211 (41.2%), and 84 (16.4%) CwD, respectively. The lowest HbA1c value was observed in the AAPS group (44 mmol/mol; IQR 8.0, p<0.0001 vs any other group), followed by Control-IQ and 780G groups (48 (IQR 11) and 52 (IQR 10) mmol/mol, respectively). All of the systems met the recommended criteria for time in range (78% in AAPS, 76% in 780G, and 75% in Control-IQ users). CwD using AAPS spent significantly more time in hypoglycemia (5% vs 2% in 780G and 3% in Control-IQ) and scored the highest GRI (32, IQR 17). The lowest GRI (27, IQR 15) was seen in 780G users. CONCLUSION: Although all HCL systems proved effective in maintaining recommended long-term glycemic control, we observed differences that illustrate strengths and weaknesses of particular systems. Our findings could help in individualizing the choice of HCL systems.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24001041
003      
CZ-PrNML
005      
20240213093556.0
007      
ta
008      
240109e20231016sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fendo.2023.1283181 $2 doi
035    __
$a (PubMed)37908748
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Santova, Alzbeta $u Department of Pediatrics, Motol University Hospital and 2nd Faculty of Medicine, Prague, Czechia $u 1st Faculty of Medicine, Charles University, Prague, Czechia
245    10
$a Are all HCL systems the same? long term outcomes of three HCL systems in children with type 1 diabetes: real-life registry-based study / $c A. Santova, L. Plachy, V. Neuman, M. Pavlikova, L. Petruzelkova, P. Konecna, P. Venhacova, J. Skvor, R. Pomahacova, D. Neumann, J. Vosahlo, J. Strnadel, K. Kocourkova, B. Obermannova, S. Pruhova, O. Cinek, Z. Sumnik
520    9_
$a OBJECTIVE: To compare parameters of glycemic control among three types of hybrid closed loop (HCL) systems in children with T1D (CwD) using population-wide data from the national pediatric diabetes registry ČENDA. METHODS: CwD aged <19 years treated with Medtronic MiniMed 780G (780G), Tandem t:slim X2 (Control-IQ) or do-it-yourself AndroidAPS (AAPS) systems for >12 months and monitored by CGM >70% of the time were included. HbA1c, times in glycemic ranges, and Glycemia Risk Index (GRI) were used for cross-sectional comparison between the HCL systems. RESULTS: Data from 512 CwD were analyzed. 780G, Control-IQ and AAPS were used by 217 (42.4%), 211 (41.2%), and 84 (16.4%) CwD, respectively. The lowest HbA1c value was observed in the AAPS group (44 mmol/mol; IQR 8.0, p<0.0001 vs any other group), followed by Control-IQ and 780G groups (48 (IQR 11) and 52 (IQR 10) mmol/mol, respectively). All of the systems met the recommended criteria for time in range (78% in AAPS, 76% in 780G, and 75% in Control-IQ users). CwD using AAPS spent significantly more time in hypoglycemia (5% vs 2% in 780G and 3% in Control-IQ) and scored the highest GRI (32, IQR 17). The lowest GRI (27, IQR 15) was seen in 780G users. CONCLUSION: Although all HCL systems proved effective in maintaining recommended long-term glycemic control, we observed differences that illustrate strengths and weaknesses of particular systems. Our findings could help in individualizing the choice of HCL systems.
650    _2
$a lidé $7 D006801
650    _2
$a dítě $7 D002648
650    12
$a diabetes mellitus 1. typu $x farmakoterapie $7 D003922
650    _2
$a glykovaný hemoglobin $7 D006442
650    _2
$a krevní glukóza $7 D001786
650    _2
$a průřezové studie $7 D003430
650    _2
$a inzulin $x terapeutické užití $7 D007328
650    _2
$a inzulinové infuzní systémy $7 D007332
650    _2
$a selfmonitoring glykemie $7 D015190
650    12
$a hypoglykemie $x chemicky indukované $x epidemiologie $7 D007003
650    _2
$a registrace $7 D012042
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Plachy, Lukas $u Department of Pediatrics, Motol University Hospital and 2nd Faculty of Medicine, Prague, Czechia
700    1_
$a Neuman, Vit $u Department of Pediatrics, Motol University Hospital and 2nd Faculty of Medicine, Prague, Czechia
700    1_
$a Pavlikova, Marketa $u Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czechia
700    1_
$a Petruzelkova, Lenka $u Department of Pediatrics, Motol University Hospital and 2nd Faculty of Medicine, Prague, Czechia
700    1_
$a Konecna, Petra $u Department of Pediatrics, University Hospital Brno, Brno, Czechia
700    1_
$a Venhacova, Petra $u Department of Pediatrics, University Hospital Olomouc, Olomouc, Czechia
700    1_
$a Skvor, Jaroslav $u Department of Pediatrics, Masaryk Hospital, Usti nad Labem, Czechia
700    1_
$a Pomahacova, Renata $u Department of Pediatrics, University Hospital Plzen, Plzen, Czechia
700    1_
$a Neumann, David $u Department of Pediatrics, University Hospital Hradec Kralove, Hradec Kralove, Czechia
700    1_
$a Vosahlo, Jan $u Department of Pediatrics, University Hospital Kralovske Vinohrady, Prague, Czechia
700    1_
$a Strnadel, Jiri $u Department of Pediatrics, University Hospital Ostrava, Ostrava, Czechia
700    1_
$a Kocourkova, Kamila $u Department of Pediatrics, Hospital Ceske Budejovice, Ceske Budejovice, Czechia
700    1_
$a Obermannova, Barbora $u Department of Pediatrics, Motol University Hospital and 2nd Faculty of Medicine, Prague, Czechia
700    1_
$a Pruhova, Stepanka $u Department of Pediatrics, Motol University Hospital and 2nd Faculty of Medicine, Prague, Czechia
700    1_
$a Cinek, Ondrej $u Department of Pediatrics, Motol University Hospital and 2nd Faculty of Medicine, Prague, Czechia
700    1_
$a Sumnik, Zdenek $u Department of Pediatrics, Motol University Hospital and 2nd Faculty of Medicine, Prague, Czechia
773    0_
$w MED00174543 $t Frontiers in endocrinology $x 1664-2392 $g Roč. 14 (20231016), s. 1283181
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37908748 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093553 $b ABA008
999    __
$a ok $b bmc $g 2049574 $s 1210735
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 14 $c - $d 1283181 $e 20231016 $i 1664-2392 $m Frontiers in endocrinology $n Front. endocrinol. $x MED00174543
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace